Cost of Glaucoma in Canada: Analyses Based on Visual Field and Physician's Assessment

Journal of Glaucoma

Volumn 12, Issue 6, 2003, Pages 456-462

  Iskedjian, Michael ^a,f   Walker, John ^a,b   Vicente, Colin ^a   Trope, Graham E ^c   Buys, Yvonne ^c   Einarson, Thomas R ^a,d   Covert, David ^e  

^a PharmIdeas Research and Consulting Inc   (Canada)

^b BROCK UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Alcon Research   (United States)

^f NONE   (Canada)

Author keywords

Cost of illness; Glaucoma; Intraocular pressure; Visual fields

Indexed keywords

ADULT; ARTICLE; CANADA; COMORBIDITY; CONTROLLED STUDY; COST CONTROL; DISEASE COURSE; DISEASE SEVERITY; EYE DISEASE; FEMALE; FOLLOW UP; GLAUCOMA; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OPEN ANGLE GLAUCOMA; PATIENT CODING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; VISUAL FIELD;

EID: 0344305396     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00061198-200312000-00002     Document Type: Article

References (16)

1. Coleman A. Glaucoma. Lancet. 1999;354:1803-1810.
2. Shirakashi M, Iwata K, Sawaguchi S, et al. Intraocular pressure-dependent progression of visual field loss in advanced primary open-angle glaucoma: A 15-year follow-up. Ophthalmologica. 1993;207:1-5.
3. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429-440.
4. Heijl A, Leske M, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression. Arch Ophthalmol. 2002;120:1268-1278.
5. Boivin J, McGregor M, Archer C. Cost effectiveness of screening for primary open angle glaucoma. J Med Screen. 1996;3:154-163.
6. Calissendorff B. Costs of medical and surgical treatment of glaucoma. Acta Ophthalmol Scand. 2001;79:286-288.
7. Oostenbrink J, Rutten-van Molken M, Sluyter-Opdenoordt T. Resource use and costs of patients with glaucoma or ocular hypertension: A one-year study based on retrospective chart review in the Netherlands. J Glaucoma. 2001;10:184-191.
8. Kobelt G, Gerdtham U, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma. 1998;7:95-104.
9. Ontario Ministry of Health. Schedule of Benefits; Physician Services under the Health Insurance Act. Toronto: Institutional Services Branch, Ministry of Health, 1993.
10. Fiscella R, Geller J, Gryz L, et al. Cost considerations of medical therapy for glaucoma. Am J Ophthalmol. 1999;128:426-433.
11. Spry P, Johnson C. Identification of progressive glaucomatous visual field loss. Surv Ophthalmol. 2002;47:158-173.
12. Kobelt G, Jonsson L, Gerdtham U, Krieglstein G. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma in Germany. Graefes' Archive for Clinical and Experimental Ophthalmology. 1998;236:811-821.
13. Vold S, Riggs W, Jackimiec J. Cost analysis of glaucoma medications: a 3-year review. J Glaucoma. 2002;11:354-358.
14. Klein R, Klein B, Scot E, et al. Age-related eye disease and survival: the Beaver Dam Eye Study. Arch Ophthalmol. 1995;113:333-339.
15. The Canadian National Institute for the Blind. Living with Vision Loss: A Handbook for Caregivers. 2002.
16. Janz N, Wren P, Lichter P, et al. The collaborative initial glaucoma treatment study: Interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001;108:1954-1965.